Nivolumab‐associated myositis myocarditis and myasthenia and anti‐striated muscle antibodies. Issue 8 (6th August 2020)

• Record Type: Journal Article
• Authors: Fazal, Marium; Prentice, David A.; Kho, Lay K.; Fysh, Edward
• Is Part Of: Internal medicine journal. Volume 50:Issue 8(2020)
• Page Start: 1003
• Page End: 1006
• Publication Date: 2020-08-06
• Subjects: immune checkpoint inhibitor -- programmed cell death protein 1, PD‐1 inhibitor -- diaphragm -- paraspinal myositis -- myocarditis -- myasthenia; Medicine -- Periodicals; 616
• DOI: 10.1111/imj.14946
• Languages: English
• ISSNs: 1444-0903

Abstract

Abstract: An 82‐year‐old man was treated with neo‐adjuvant nivolumab (programmed cell death protein 1 or PD‐1 inhibitor) for local recurrence of melanoma developed myositis, myocarditis and a myasthenic‐like syndrome with a fatal outcome. The occurrence of these three conditions may constitute a new immune checkpoint‐induced syndrome. The relevance of the clinical features and the immunology is discussed. This case highlights the special role of anti‐striated muscle antibodies as a predictor of mortality.